We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ALLR

Price
0.93
Stock movement up
+0.06 (6.71%)
Company name
Allarity Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
13.60M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-92.97%
3 year return
-99.15%
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ALLR does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.86
Daily high0.98
Daily low0.86
Daily Volume815K
All-time high10605000.00
1y analyst estimate9.00
Beta0.07
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ALLRS&P500
Current price drop from All-time high-100.00%-3.04%
Highest price drop-100.00%-56.47%
Date of highest drop20 Jun 20259 Mar 2009
Avg drop from high-93.73%-11.04%
Avg time to new high438 days12 days
Max time to new high876 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ALLR (Allarity Therapeutics Inc) company logo
Marketcap
13.60M
Marketcap category
Small-cap
Description
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Employees
6
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...